<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd">
	<channel>
        		<title>QB3 Bioentrepreneurship Podcast</title>
		<link>http://cit.ucsf.edu/podcast/description.php?id=47856118-d9cf-4011-9961-bd17522e2c56</link>
		<description>QB3 Bioentrepreneurship Podcast</description>
		<docs>http://blogs.law.harvard.edu/tech/rss</docs>
		<language>en-us</language>
		<copyright>2012 Regents of the University of California</copyright>
		<managingEditor>citstaff@ucsf.edu</managingEditor>
		<webMaster>citstaff@ucsf.edu</webMaster>
		<category>Education</category>
		<pubDate>Wed, 23 May 2012 15:01:43 PDT</pubDate>
		<lastBuildDate>Wed, 23 May 2012 15:01:43 PDT</lastBuildDate>
		<image>
			<url>http://cit.ucsf.edu/podcast/images/ucsf_podcast_rss2.jpg</url>
			<title>Podcast@UCSF</title>
			<link>http://cit.ucsf.edu/podcast/description.php?id=47856118-d9cf-4011-9961-bd17522e2c56</link>
			<width>144</width>
			<height>144</height>
		</image>
		<itunes:author>citstaff@ucsf.edu</itunes:author>
  		<itunes:subtitle>QB3 Bioentrepreneurship Podcast</itunes:subtitle>
  		<itunes:summary>QB3 Bioentrepreneurship Podcast</itunes:summary>
  		<itunes:keywords>
  		</itunes:keywords>
  		<itunes:explicit>no</itunes:explicit>
		<itunes:image href="http://cit.ucsf.edu/podcast/images/ucsf_podcast_itunes.jpg"/>
  		<itunes:owner>
   				<itunes:name>UCSF Library and Center for Knowledge Management</itunes:name>
   				<itunes:email>citstaff@ucsf.edu</itunes:email>
  		</itunes:owner>
  		<itunes:block>yes</itunes:block>
  		<itunes:category text="Education" />
		<item>
			<title>Podcast migrated to http://feeds.feedburner.com/QB3Podcast</title>
			<link>http://cit.ucsf.edu/podcast/episode/4a374b6f-7393-4591-9984-b27e06a4c0ad/podcast_migrated_to_httpfeeds.feedburner.comqb3podcast.pdf</link>
			<description>Dear listeners:

We have moved to http://feeds.feedburner.com/QB3Podcast. Please update your podcast feed. You can access it on the iTunes Store here: 

http://itunes.apple.com/us/podcast/qb3-bioentrepreneurship-podcast/id529607950

Thank you for your continued support! 


Sincerely,

QB3 Bioentrepreneurship Podcast</description>
			<author>Christine Fu</author>
			<pubDate>Wed, 23 May 2012 15:01:43 PDT</pubDate>
			<comments>http://cit.ucsf.edu/podcast/episode/4a374b6f-7393-4591-9984-b27e06a4c0ad/podcast_migrated_to_httpfeeds.feedburner.comqb3podcast.pdf</comments>
			<enclosure url="http://cit.ucsf.edu/podcast/episode/4a374b6f-7393-4591-9984-b27e06a4c0ad/podcast_migrated_to_httpfeeds.feedburner.comqb3podcast.pdf" length="9321"	type="application/pdf" />
			<guid>http://cit.ucsf.edu/podcast/episode/4a374b6f-7393-4591-9984-b27e06a4c0ad/podcast_migrated_to_httpfeeds.feedburner.comqb3podcast.pdf</guid>
			<itunes:author>Christine Fu</itunes:author>
			<itunes:subtitle>Dear listeners:

We have moved to http://feeds.feedburner.com/QB3Podcast. Please update your podcast feed. You can access it on the iTunes Store here: 

http://itunes.apple.com/us/podcast/qb3-bioentrepreneurship-podcast/id529607950

Thank you for your continued support! 


Sincerely,

QB3 Bioentrepreneurship Podcast</itunes:subtitle>
   			<itunes:summary>Dear listeners:

We have moved to http://feeds.feedburner.com/QB3Podcast. Please update your podcast feed. You can access it on the iTunes Store here: 

http://itunes.apple.com/us/podcast/qb3-bioentrepreneurship-podcast/id529607950

Thank you for your continued support! 


Sincerely,

QB3 Bioentrepreneurship Podcast</itunes:summary>
   			<itunes:explicit>no</itunes:explicit>
		</item>
		<item>
			<title>Freakonomics of Factors that Determine Failure of a Biotech company - M Ken Kengatharan - Altheos</title>
			<link>http://cit.ucsf.edu/podcast/episode/4bc88503-648b-46a1-9d55-c023cf58e18c/freakonomics_of_factors_that_determine_failure_of_a_biotech_company_-_m_ken_kengatharan_-_altheos.pdf</link>
			<description>Dr. M. (Ken) Kengatharan is the co-founder of several biotech companies, including Altheos, Armetheo, and Athenagen (CoMentis), which completed a significant deal with Astellas Pharmaceutical in 2008. He’s also a general partner at the biotech incubator fund Atheneos Capital. In this seminar, Dr. Kengatharan talks about several unconventional factors that determine the failure of biotechnology startups.</description>
			<author>Christine Fu</author>
			<pubDate>Mon, 21 May 2012 18:51:01 PDT</pubDate>
			<comments>http://cit.ucsf.edu/podcast/episode/4bc88503-648b-46a1-9d55-c023cf58e18c/freakonomics_of_factors_that_determine_failure_of_a_biotech_company_-_m_ken_kengatharan_-_altheos.pdf</comments>
			<enclosure url="http://cit.ucsf.edu/podcast/episode/4bc88503-648b-46a1-9d55-c023cf58e18c/freakonomics_of_factors_that_determine_failure_of_a_biotech_company_-_m_ken_kengatharan_-_altheos.pdf" length="2347447"	type="application/pdf" />
			<guid>http://cit.ucsf.edu/podcast/episode/4bc88503-648b-46a1-9d55-c023cf58e18c/freakonomics_of_factors_that_determine_failure_of_a_biotech_company_-_m_ken_kengatharan_-_altheos.pdf</guid>
			<itunes:author>Christine Fu</itunes:author>
			<itunes:subtitle>Dr. M. (Ken) Kengatharan is the co-founder of several biotech companies, including Altheos, Armetheo, and Athenagen (CoMentis), which completed a significant deal with Astellas Pharmaceutical in 2008. He’s also a general partner at the biotech incubator fund Atheneos Capital. In this seminar, Dr. Kengatharan talks about several unconventional factors that determine the failure of biotechnology startups.</itunes:subtitle>
   			<itunes:summary>Dr. M. (Ken) Kengatharan is the co-founder of several biotech companies, including Altheos, Armetheo, and Athenagen (CoMentis), which completed a significant deal with Astellas Pharmaceutical in 2008. He’s also a general partner at the biotech incubator fund Atheneos Capital. In this seminar, Dr. Kengatharan talks about several unconventional factors that determine the failure of biotechnology startups.</itunes:summary>
   			<itunes:explicit>no</itunes:explicit>
		</item>
		<item>
			<title>Freakonomics of Factors that Determine Failure of a Biotech company - M Ken Kengatharan - Altheos</title>
			<link>http://cit.ucsf.edu/podcast/episode/14a5409e-d550-4779-b4dc-44b7a26039a3/freakonomics_of_factors_that_determine_failure_of_a_biotech_company_-_m_ken_kengatharan_-_altheos.mp3</link>
			<description>Dr. M. (Ken) Kengatharan is the co-founder of several biotech companies, including Altheos, Armetheo, and Athenagen (CoMentis), which completed a significant deal with Astellas Pharmaceutical in 2008. He’s also a general partner at the biotech incubator fund Atheneos Capital. In this seminar, Dr. Kengatharan talks about several unconventional factors that determine the failure of biotechnology startups.</description>
			<author>Christine Fu</author>
			<pubDate>Mon, 21 May 2012 18:50:01 PDT</pubDate>
			<comments>http://cit.ucsf.edu/podcast/episode/14a5409e-d550-4779-b4dc-44b7a26039a3/freakonomics_of_factors_that_determine_failure_of_a_biotech_company_-_m_ken_kengatharan_-_altheos.mp3</comments>
			<enclosure url="http://cit.ucsf.edu/podcast/episode/14a5409e-d550-4779-b4dc-44b7a26039a3/freakonomics_of_factors_that_determine_failure_of_a_biotech_company_-_m_ken_kengatharan_-_altheos.mp3" length="20415890"	type="audio/x-mpeg" />
			<guid>http://cit.ucsf.edu/podcast/episode/14a5409e-d550-4779-b4dc-44b7a26039a3/freakonomics_of_factors_that_determine_failure_of_a_biotech_company_-_m_ken_kengatharan_-_altheos.mp3</guid>
			<itunes:author>Christine Fu</itunes:author>
			<itunes:subtitle>Dr. M. (Ken) Kengatharan is the co-founder of several biotech companies, including Altheos, Armetheo, and Athenagen (CoMentis), which completed a significant deal with Astellas Pharmaceutical in 2008. He’s also a general partner at the biotech incubator fund Atheneos Capital. In this seminar, Dr. Kengatharan talks about several unconventional factors that determine the failure of biotechnology startups.</itunes:subtitle>
   			<itunes:summary>Dr. M. (Ken) Kengatharan is the co-founder of several biotech companies, including Altheos, Armetheo, and Athenagen (CoMentis), which completed a significant deal with Astellas Pharmaceutical in 2008. He’s also a general partner at the biotech incubator fund Atheneos Capital. In this seminar, Dr. Kengatharan talks about several unconventional factors that determine the failure of biotechnology startups.</itunes:summary>
   			<itunes:explicit>no</itunes:explicit>
		</item>
		<item>
			<title>Today’s Biomedical Innovation: Lost in Translation? - Janet Woodcock - FDA</title>
			<link>http://cit.ucsf.edu/podcast/episode/b7cd0442-499b-4708-9102-b1eea1a540c7/today’s_biomedical_innovation_lost_in_translation_-_janet_woodcock_-_fda.pdf</link>
			<description>Dr. Janet Woodcock, director of FDA’s Center for Drug Evaluation and Research, gave a recent QB3 lecture at UCSF Mission Bay. Dr. Woodcock discussed the challenges of translating biomedical innovations into the clinic. She pointed out that we need to develop new paradigms for evaluating diagnostic, therapeutic and preventive interventions, that are faster, more efficient and more informative. She also called for academic medical centers to play a bigger role in drug development, in order to lower cost and reduce failure.</description>
			<author>Christine Fu</author>
			<pubDate>Wed, 09 May 2012 10:28:45 PDT</pubDate>
			<comments>http://cit.ucsf.edu/podcast/episode/b7cd0442-499b-4708-9102-b1eea1a540c7/today’s_biomedical_innovation_lost_in_translation_-_janet_woodcock_-_fda.pdf</comments>
			<enclosure url="http://cit.ucsf.edu/podcast/episode/b7cd0442-499b-4708-9102-b1eea1a540c7/today’s_biomedical_innovation_lost_in_translation_-_janet_woodcock_-_fda.pdf" length="624850"	type="application/pdf" />
			<guid>http://cit.ucsf.edu/podcast/episode/b7cd0442-499b-4708-9102-b1eea1a540c7/today’s_biomedical_innovation_lost_in_translation_-_janet_woodcock_-_fda.pdf</guid>
			<itunes:author>Christine Fu</itunes:author>
			<itunes:subtitle>Dr. Janet Woodcock, director of FDA’s Center for Drug Evaluation and Research, gave a recent QB3 lecture at UCSF Mission Bay. Dr. Woodcock discussed the challenges of translating biomedical innovations into the clinic. She pointed out that we need to develop new paradigms for evaluating diagnostic, therapeutic and preventive interventions, that are faster, more efficient and more informative. She also called for academic medical centers to play a bigger role in drug development, in order to lower cost and reduce failure.</itunes:subtitle>
   			<itunes:summary>Dr. Janet Woodcock, director of FDA’s Center for Drug Evaluation and Research, gave a recent QB3 lecture at UCSF Mission Bay. Dr. Woodcock discussed the challenges of translating biomedical innovations into the clinic. She pointed out that we need to develop new paradigms for evaluating diagnostic, therapeutic and preventive interventions, that are faster, more efficient and more informative. She also called for academic medical centers to play a bigger role in drug development, in order to lower cost and reduce failure.</itunes:summary>
   			<itunes:explicit>no</itunes:explicit>
		</item>
		<item>
			<title>Today’s Biomedical Innovation: Lost in Translation? - Janet Woodcock - FDA</title>
			<link>http://cit.ucsf.edu/podcast/episode/e4b93293-0b2f-4891-a3cf-a0f6a96c802c/today’s_biomedical_innovation_lost_in_translation_-_janet_woodcock_-_fda.mp3</link>
			<description>Dr. Janet Woodcock, director of FDA’s Center for Drug Evaluation and Research, gave a recent QB3 lecture at UCSF Mission Bay. Dr. Woodcock discussed the challenges of translating biomedical innovations into the clinic. She pointed out that we need to develop new paradigms for evaluating diagnostic, therapeutic and preventive interventions, that are faster, more efficient and more informative. She also called for academic medical centers to play a bigger role in drug development, in order to lower cost and reduce failure.</description>
			<author>Christine Fu</author>
			<pubDate>Wed, 09 May 2012 10:21:13 PDT</pubDate>
			<comments>http://cit.ucsf.edu/podcast/episode/e4b93293-0b2f-4891-a3cf-a0f6a96c802c/today’s_biomedical_innovation_lost_in_translation_-_janet_woodcock_-_fda.mp3</comments>
			<enclosure url="http://cit.ucsf.edu/podcast/episode/e4b93293-0b2f-4891-a3cf-a0f6a96c802c/today’s_biomedical_innovation_lost_in_translation_-_janet_woodcock_-_fda.mp3" length="31103526"	type="audio/x-mpeg" />
			<guid>http://cit.ucsf.edu/podcast/episode/e4b93293-0b2f-4891-a3cf-a0f6a96c802c/today’s_biomedical_innovation_lost_in_translation_-_janet_woodcock_-_fda.mp3</guid>
			<itunes:author>Christine Fu</itunes:author>
			<itunes:subtitle>Dr. Janet Woodcock, director of FDA’s Center for Drug Evaluation and Research, gave a recent QB3 lecture at UCSF Mission Bay. Dr. Woodcock discussed the challenges of translating biomedical innovations into the clinic. She pointed out that we need to develop new paradigms for evaluating diagnostic, therapeutic and preventive interventions, that are faster, more efficient and more informative. She also called for academic medical centers to play a bigger role in drug development, in order to lower cost and reduce failure.</itunes:subtitle>
   			<itunes:summary>Dr. Janet Woodcock, director of FDA’s Center for Drug Evaluation and Research, gave a recent QB3 lecture at UCSF Mission Bay. Dr. Woodcock discussed the challenges of translating biomedical innovations into the clinic. She pointed out that we need to develop new paradigms for evaluating diagnostic, therapeutic and preventive interventions, that are faster, more efficient and more informative. She also called for academic medical centers to play a bigger role in drug development, in order to lower cost and reduce failure.</itunes:summary>
   			<itunes:explicit>no</itunes:explicit>
		</item>
		<item>
			<title>Scientific Entrepreneurship: Building a Synthetic Career - Louis Lange - Asset Management Company</title>
			<link>http://cit.ucsf.edu/podcast/episode/7c9a8305-6f10-4100-aede-96e5c97d9780/scientific_entrepreneurship_building_a_synthetic_career_-_louis_lange_-_asset_management_company.mp3</link>
			<description>Louis Lange, general partner at Asset Management Company, shares advice and perspective from his career, starting as an academician in molecular cardiology, to a biotech entrepreneur, and to his current work as a venture capitalist.</description>
			<author>Christine Fu</author>
			<pubDate>Thu, 12 Apr 2012 03:18:34 PDT</pubDate>
			<comments>http://cit.ucsf.edu/podcast/episode/7c9a8305-6f10-4100-aede-96e5c97d9780/scientific_entrepreneurship_building_a_synthetic_career_-_louis_lange_-_asset_management_company.mp3</comments>
			<enclosure url="http://cit.ucsf.edu/podcast/episode/7c9a8305-6f10-4100-aede-96e5c97d9780/scientific_entrepreneurship_building_a_synthetic_career_-_louis_lange_-_asset_management_company.mp3" length="17185229"	type="audio/x-mpeg" />
			<guid>http://cit.ucsf.edu/podcast/episode/7c9a8305-6f10-4100-aede-96e5c97d9780/scientific_entrepreneurship_building_a_synthetic_career_-_louis_lange_-_asset_management_company.mp3</guid>
			<itunes:author>Christine Fu</itunes:author>
			<itunes:subtitle>Louis Lange, general partner at Asset Management Company, shares advice and perspective from his career, starting as an academician in molecular cardiology, to a biotech entrepreneur, and to his current work as a venture capitalist.</itunes:subtitle>
   			<itunes:summary>Louis Lange, general partner at Asset Management Company, shares advice and perspective from his career, starting as an academician in molecular cardiology, to a biotech entrepreneur, and to his current work as a venture capitalist.</itunes:summary>
   			<itunes:explicit>no</itunes:explicit>
		</item>
		<item>
			<title>A Current Perspective on Investing in the Life Sciences – Dennis Henner - Clarus Ventures</title>
			<link>http://cit.ucsf.edu/podcast/episode/f1ab5d97-9d38-4ee8-89b0-4c54a3b42d83/a_current_perspective_on_investing_in_the_life_sciences_–_dennis_henner_-_clarus_ventures.mp3</link>
			<description>Dennis Henner, Managing Director of Clarus Ventures, shares experiences and insights from his 20-year tenure at Genentech. As a venture capitalist, Henner also provides his perspective on the current climate for investment in life sciences.</description>
			<author>Christine Fu</author>
			<pubDate>Thu, 12 Apr 2012 03:01:16 PDT</pubDate>
			<comments>http://cit.ucsf.edu/podcast/episode/f1ab5d97-9d38-4ee8-89b0-4c54a3b42d83/a_current_perspective_on_investing_in_the_life_sciences_–_dennis_henner_-_clarus_ventures.mp3</comments>
			<enclosure url="http://cit.ucsf.edu/podcast/episode/f1ab5d97-9d38-4ee8-89b0-4c54a3b42d83/a_current_perspective_on_investing_in_the_life_sciences_–_dennis_henner_-_clarus_ventures.mp3" length="18780591"	type="audio/x-mpeg" />
			<guid>http://cit.ucsf.edu/podcast/episode/f1ab5d97-9d38-4ee8-89b0-4c54a3b42d83/a_current_perspective_on_investing_in_the_life_sciences_–_dennis_henner_-_clarus_ventures.mp3</guid>
			<itunes:author>Christine Fu</itunes:author>
			<itunes:subtitle>Dennis Henner, Managing Director of Clarus Ventures, shares experiences and insights from his 20-year tenure at Genentech. As a venture capitalist, Henner also provides his perspective on the current climate for investment in life sciences.</itunes:subtitle>
   			<itunes:summary>Dennis Henner, Managing Director of Clarus Ventures, shares experiences and insights from his 20-year tenure at Genentech. As a venture capitalist, Henner also provides his perspective on the current climate for investment in life sciences.</itunes:summary>
   			<itunes:explicit>no</itunes:explicit>
		</item>
		<item>
			<title>The Target Product Profile: Converting Discoveries into Companies - Patrick Scannon - XOMA</title>
			<link>http://cit.ucsf.edu/podcast/episode/1ddada83-7cef-4c54-8b21-7b0e9dff84a1/the_target_product_profile_converting_discoveries_into_companies_-_patrick_scannon_-_xoma.mp3</link>
			<description>Patrick Scannon, XOMA’s Founder, Executive Vice President, and Chief Scientific Officer, presents a primer on the target product profile, and how it is adaptable as a communication tool between academic discoverers and investors.</description>
			<author>Christine Fu</author>
			<pubDate>Thu, 12 Apr 2012 02:48:58 PDT</pubDate>
			<comments>http://cit.ucsf.edu/podcast/episode/1ddada83-7cef-4c54-8b21-7b0e9dff84a1/the_target_product_profile_converting_discoveries_into_companies_-_patrick_scannon_-_xoma.mp3</comments>
			<enclosure url="http://cit.ucsf.edu/podcast/episode/1ddada83-7cef-4c54-8b21-7b0e9dff84a1/the_target_product_profile_converting_discoveries_into_companies_-_patrick_scannon_-_xoma.mp3" length="22772845"	type="audio/x-mpeg" />
			<guid>http://cit.ucsf.edu/podcast/episode/1ddada83-7cef-4c54-8b21-7b0e9dff84a1/the_target_product_profile_converting_discoveries_into_companies_-_patrick_scannon_-_xoma.mp3</guid>
			<itunes:author>Christine Fu</itunes:author>
			<itunes:subtitle>Patrick Scannon, XOMA’s Founder, Executive Vice President, and Chief Scientific Officer, presents a primer on the target product profile, and how it is adaptable as a communication tool between academic discoverers and investors.</itunes:subtitle>
   			<itunes:summary>Patrick Scannon, XOMA’s Founder, Executive Vice President, and Chief Scientific Officer, presents a primer on the target product profile, and how it is adaptable as a communication tool between academic discoverers and investors.</itunes:summary>
   			<itunes:explicit>no</itunes:explicit>
		</item>
		<item>
			<title>The Target Product Profile: Converting Discoveries into Companies - Patrick Scannon - XOMA - PDF</title>
			<link>http://cit.ucsf.edu/podcast/episode/775dd773-3c00-4d86-9a33-248357563e49/the_target_product_profile_converting_discoveries_into_companies_-_patrick_scannon_-_xoma_-_pdf.pdf</link>
			<description>Patrick Scannon, XOMA’s Founder, Executive Vice President, and Chief Scientific Officer, presents a primer on the target product profile, and how it is adaptable as a communication tool between academic discoverers and investors.</description>
			<author>Christine Fu</author>
			<pubDate>Thu, 12 Apr 2012 02:48:19 PDT</pubDate>
			<comments>http://cit.ucsf.edu/podcast/episode/775dd773-3c00-4d86-9a33-248357563e49/the_target_product_profile_converting_discoveries_into_companies_-_patrick_scannon_-_xoma_-_pdf.pdf</comments>
			<enclosure url="http://cit.ucsf.edu/podcast/episode/775dd773-3c00-4d86-9a33-248357563e49/the_target_product_profile_converting_discoveries_into_companies_-_patrick_scannon_-_xoma_-_pdf.pdf" length="1917293"	type="application/pdf" />
			<guid>http://cit.ucsf.edu/podcast/episode/775dd773-3c00-4d86-9a33-248357563e49/the_target_product_profile_converting_discoveries_into_companies_-_patrick_scannon_-_xoma_-_pdf.pdf</guid>
			<itunes:author>Christine Fu</itunes:author>
			<itunes:subtitle>Patrick Scannon, XOMA’s Founder, Executive Vice President, and Chief Scientific Officer, presents a primer on the target product profile, and how it is adaptable as a communication tool between academic discoverers and investors.</itunes:subtitle>
   			<itunes:summary>Patrick Scannon, XOMA’s Founder, Executive Vice President, and Chief Scientific Officer, presents a primer on the target product profile, and how it is adaptable as a communication tool between academic discoverers and investors.</itunes:summary>
   			<itunes:explicit>no</itunes:explicit>
		</item>
		<item>
			<title>Secrets of Early Stage Life Science Startup Funding - John Steuart - Claremont Creek Ventures</title>
			<link>http://cit.ucsf.edu/podcast/episode/d1e31771-1412-427d-bb11-5c84b149bc29/secrets_of_early_stage_life_science_startup_funding_-_john_steuart_-_claremont_creek_ventures.mp3</link>
			<description>Claremont Creek Ventures managing director John Steuart shares insight on early stage life science startup funding with QB3 associate director Douglas Crawford in a QED seminar.</description>
			<author>Christine Fu</author>
			<pubDate>Thu, 12 Apr 2012 02:22:06 PDT</pubDate>
			<comments>http://cit.ucsf.edu/podcast/episode/d1e31771-1412-427d-bb11-5c84b149bc29/secrets_of_early_stage_life_science_startup_funding_-_john_steuart_-_claremont_creek_ventures.mp3</comments>
			<enclosure url="http://cit.ucsf.edu/podcast/episode/d1e31771-1412-427d-bb11-5c84b149bc29/secrets_of_early_stage_life_science_startup_funding_-_john_steuart_-_claremont_creek_ventures.mp3" length="20103562"	type="audio/x-mpeg" />
			<guid>http://cit.ucsf.edu/podcast/episode/d1e31771-1412-427d-bb11-5c84b149bc29/secrets_of_early_stage_life_science_startup_funding_-_john_steuart_-_claremont_creek_ventures.mp3</guid>
			<itunes:author>Christine Fu</itunes:author>
			<itunes:subtitle>Claremont Creek Ventures managing director John Steuart shares insight on early stage life science startup funding with QB3 associate director Douglas Crawford in a QED seminar.</itunes:subtitle>
   			<itunes:summary>Claremont Creek Ventures managing director John Steuart shares insight on early stage life science startup funding with QB3 associate director Douglas Crawford in a QED seminar.</itunes:summary>
   			<itunes:explicit>no</itunes:explicit>
		</item>
	</channel>
</rss>